Skip to main content
HBM Holdings Limited logo

HBM Holdings Limited — Investor Relations & Filings

Ticker · 2142 ISIN · KYG4403H1002 LEI · 254900ZT5QBQG3JL9J21 HKEX Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2026-03-05 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2142

About HBM Holdings Limited

http://www.harbourbiomed.com

HBM Holdings Limited is a global biopharmaceutical company specializing in the discovery, development, and commercialization of novel antibody therapeutics. The company focuses on addressing unmet medical needs in oncology, immuno-oncology, and immunological diseases. HBM's core technological foundation is the integrated Harbour antibody platform, featuring the proprietary Harbour Mice® technology. This platform is engineered to generate highly diverse, fully human monoclonal antibodies in both the conventional two heavy/two light chain (H2L2) format and the heavy chain only (HCAb) format. Utilizing the HCAb format, HBM develops advanced next-generation biologics, including HCAb-based immune cell engagers (HBICE®). The company maintains a robust pipeline of differentiated clinical assets and actively engages in technology licensing and strategic collaborations to accelerate the development of innovative therapies.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory filing used by listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Earnings Release' or 'Annual Report' but is a mandatory regulatory disclosure required by the Exchange Listing Rules. Therefore, it is classified as a Regulatory Filing (RNS).
2026-03-05 English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO LICENSE AGREEMENT AND EQUITY PARTNERSHIP AGREEMENT WITH SOLSTICE ONCOLOGY FOR HBM4003
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement regarding a license agreement and equity partnership between HBM Holdings Limited and Solstice Oncology. It details the financial terms of the deal, including upfront payments and potential milestone payments. Since this relates to a strategic business partnership and licensing deal, it falls under the category of M&A Activity (TAR), which covers merger proposals, takeover bids, and significant strategic business partnerships/licensing agreements.
2026-02-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange. This specific form tracks movements in securities, including changes in issued shares, treasury shares, and share options. According to the filing definitions, announcements regarding new share issues, stock splits, or capital changes are classified as 'Share Issue/Capital Change' (SHA). While it is a regulatory filing, it is specifically focused on capital structure changes, making SHA the most precise category.
2026-02-06 English
POSITIVE PROFIT ALERT
Earnings Release Classification · 1% confidence The document is a 'Positive Profit Alert' issued by HBM Holdings Limited. It provides a preliminary assessment of financial performance for the year ended 31 December 2025, ahead of the full annual results publication. This type of announcement is a standard regulatory requirement for listed companies to inform the market of significant changes in financial expectations. It is not the full annual report (10-K) or an earnings release (ER) in the sense of a full report, but rather a specific regulatory disclosure regarding profit expectations. Therefore, it fits best as an Earnings Release (ER) or a Regulatory Filing (RNS). Given the specific nature of a 'Positive Profit Alert' as a preliminary financial announcement, 'ER' is the most accurate classification. FY 2025
2026-02-04 English
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE
Transaction in Own Shares Classification · 1% confidence The document is a voluntary announcement by HBM Holdings Limited regarding its intention to repurchase shares in the open market. It explicitly discusses the 'Repurchase Mandate' and the company's intent to buy back its own shares to maximize shareholder value. This falls directly under the category of 'Transaction in Own Shares' (POS), which covers share repurchases.
2026-01-29 English
VOLUNTARY ANNOUNCEMENT - EXERCISE OF WARRANT UNDER LICENSE AND COLLABORATION AGREEMENT WITH SPRUCE BIOSCIENCES INC.
Capital/Financing Update Classification · 1% confidence The document is a voluntary announcement regarding the exercise of a warrant under a license and collaboration agreement. It details a specific corporate action (the acquisition of shares in Spruce Biosciences Inc. via warrant exercise) and confirms that it does not meet the threshold for mandatory disclosure under the Listing Rules. Since it is a general regulatory announcement regarding a business update that does not fit into specific categories like M&A, share buybacks, or director dealings, it is classified as a Regulatory Filing (RNS).
2026-01-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.